Fig. 4

DKC1 as a predictor for Sunitinib response in female but not male ccRCC patients. The analyses were performed on IMmotion 151 (Discovery cohort A–D) and IMmotion150 (validation cohort, E–H) treated with Sunitinib. IMmotion 151 cohort: (A) differences in Sunitinib response (left) and PFS (right) between female and male ccRCC patients. (B) Differences in Sunitinib response (left) and PFS (right) between DKC1-high and low groups of ccRCC patients (both sexes). C Differences in Sunitinib response (left) and PFS (right) between DKC1-high and low groups in female patients. D Differences in Sunitinib response (left) and PFS (right) between DKC1-high and low groups in male patients. IMmotion 150 cohort. E Differences in Sunitinib response (left) and PFS (right) between female and male ccRCC patients. F Differences in Sunitinib response (left) and PFS (right) between DKC1-high and low groups of ccRCC patients. G Differences in Sunitinib response (left) and PFS (right) between DKC1-high and low groups in female patients. H Differences in Sunitinib response (left) and PFS (right) between DKC1-high and low groups in male patients. CRPR: complete and partial remission; SD: stable disease; PD: progressive disease. Left panels: Fisher’s exact test and right panels: log-rank test